Hydrogen-deuterium exchange mass spectrometry (HDX-MS) has developed into a powerful tool for investigating biopharmaceuticals, protein interactions, and membrane protein dynamics. Since 2010 HDX-MS data has helped substantiate and protect >110 US patents. Increasingly, biopharma companies provide HDX-MS data to support their biologics license applications (BLAs). However, for HDX-MS to emerge as a tool for quality control and similarity evaluations of biotherapeutics, an understanding of HDX-MS reproducibility is needed. NIST has determined the precision of bottom-up HDX-MS (Figure 1) by the analysis of 78,900 peptide measurements from 15 laboratories. We have also developed improvements to HDX-MS methodology, including automated measurements of membrane protein drug targets and chromatography instrumentation, operating at -30 oC, that improves HDX-MS measurements by arresting back-exchange.
Learning Objectives:
1. An interlaboratory comparison involving 15 laboratory cohort has established reproducibility of HDX-MS, facilitating its use in commerce.
2. NIST has developed a method that allows automated HDX-MS studies of membrane proteins, which comprise 60% of all drug targets.
3. Chromatography at -30 oC reduces H for D back-exchange to 5 %, which improves the D-uptake measurement by 3x to 10x.
Mass Spectrometry
Chromatography
Laboratory Testing
Biomarkers
Life Sciences
Lab Automation
Biotechnology
Physical Chemistry
Diagnostics
Health
Research And Development
Cancer Diagnostics
Raman Spectroscopy
Molecular Diagnostics
Proteomics
North America57%
Asia14%
Europe14%
Africa14%
Website Visitors100%
Student33%
Research Scientist33%
Facility/Department Manager17%
Medical Laboratory Technician17%
Academic Institution43%
Clinical Laboratory14%
Research Institute14%
Manufacturer - Other14%
Manufacturer & Biotech/pharma14%